Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms (Q35058227)

6 August 2017

1 reference

title

Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms (English)

1 reference

6 August 2017

1 reference

Callahan AS 3rd

1

1 reference

6 August 2017

1 January 2003

1 reference

Current Atherosclerosis Reports

6 August 2017

1 reference

6 August 2017

5

1 reference

6 August 2017

1

1 reference

6 August 2017

33-37

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-003-0066-2

6 August 2017

0 references

cites work

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-003-0066-2

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-003-0066-2

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-003-0066-2

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-003-0066-2

Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-003-0066-2

State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-003-0066-2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

12 December 2020

Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration

1 reference

12 December 2020

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Coronary risk factors and plaque morphology in men with coronary disease who died suddenly

1 reference

12 December 2020

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

1 reference

12 December 2020

High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound

1 reference

12 December 2020

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Range of serum cholesterol values in the population developing coronary artery disease

1 reference

12 December 2020

Low-density lipoprotein-independent effects of statins

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

1 reference

12 December 2020

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

1 reference

12 December 2020

Lipids, risk factors and ischaemic heart disease

1 reference

12 December 2020

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

1 reference

12 December 2020

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins

1 reference

12 December 2020

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

12 December 2020

10.1007/S11883-003-0066-2

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12562540